Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV is increasing its global peak sales estimate for its oral bradykinin B2 receptor antagonist, deucrictibant, to $1.65 billion by 2037, reflecting strengthened market potential as it advances toward pivotal Phase 3 studies for treating and preventing HAE attacks. Data from clinical studies demonstrate that 100% of participants achieved "well-controlled HAE" status and reported significant improvements in health-related quality of life, which underlines the drug's clinical efficacy and potential to address an unmet medical need in a population characterized by a rare disease incidence of approximately 1:100,000 to 1:500,000. The consistency of positive results across extensive data sets, including rapid and durable relief from HAE symptoms, positions deucrictibant as a promising and potentially best-in-class oral treatment option.

Pharvaris NV faces significant challenges in its drug development, primarily due to inadequate de-risking of bradykinin B2 receptor antagonism in chronic prophylaxis settings, which raises concerns over the effectiveness of its product pipeline. The highly competitive market for hereditary angioedema (HAE) treatment features established segment leaders with proven therapies, likely diminishing the potential market entry and acceptance for Pharvaris’s deucrictibant. Additionally, the impending approval of multiple subcutaneous therapies within the next 36 months poses a substantial threat, as these options may not only capture market share from Pharvaris but also hinder the overall adoption of its oral treatment approach.